Trends in HR plus metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2-and HER2+metastatic breast cancer

被引：4

作者：

Brufsky, Adam ^{[1
]}

Kwan, Marilyn L. ^{[2
]}

Sandin, Rickard ^{[3
]}

Stergiopoulos, Stella ^{[4
]}

Karanth, Siddharth ^{[5
]}

Cha-Silva, Ashley S. ^{[4
]}

Makari, Doris ^{[4
]}

Goyal, Ravi K. ^{[5
]}

机构：

[1] Univ Pittsburgh, UPMC Hillman Canc Ctr, Med Ctr, Pittsburgh, PA 15260 USA

[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA

[3] Pfizer AB, Stockholm, Sweden

[4] Pfizer Inc, New York, NY USA

[5] RTI Hlth Solut, Res Triangle Pk, NC USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2024年 / 208卷 / 02期

关键词：

Metastatic breast cancer; CDK4/6; inhibitor; HER2; Elderly; SEER database; CLINICAL-TRIALS; ENDOCRINE THERAPY; DRUG REGISTRATION; AMERICAN SOCIETY; DOUBLE-BLIND; PALBOCICLIB; FULVESTRANT; ABEMACICLIB; EXPERIENCE; RIBOCICLIB;

D O I：

10.1007/s10549-024-07469-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However, investigations of survival gains in broader HR+/HER2- mBC populations using epidemiological approaches are limited. Methods This retrospective study used SEER registry data to assess breast cancer-specific survival (BCSS) in patients diagnosed with HR+/HER2- de novo mBC from 2010 to 2019. Kaplan-Meier and Cox proportional hazards models were used to compare BCSS in patients diagnosed before (2010-2013 with follow-up to 2014) and after (2015-2018 with follow-up to 2019) the 2015 guideline recommendations for CDK4/6i use. A comparison was made to patients with HR+/HER2-positive (HER2+) de novo mBC, for which no major guideline changes occurred during 2015-2018. Results Data from 11,467 women with HR+/HER2- mBC and 3260 women with HR+/HER2+ mBC were included. After baseline characteristic adjustment, patients with HR+/HER2- mBC diagnosed post-2015 (n = 6163), had an approximately 10% reduction in risk of BC-specific death compared with patients diagnosed pre-2015 (n = 5304; HR = 0.895, p < 0.0001). Conversely, no significant change was observed in HR+/HER2+ BCSS post-2015 (n = 1798) versus pre-2015 (n = 1462). Similar results were found in patients aged >= 65 years. Conclusion Using one of the largest US population-based longitudinal cancer databases, significant improvements in BCSS were noted in patients with HR+/HER2- mBC post-2015 versus pre-2015, potentially due to the introduction of CDK4/6i post-2015. No significant improvement in BCSS was observed in patients with HR+/HER2+ mBC post-2015 versus pre-2015, likely due to the availability of HER2-directed therapies in both time periods.

引用

页码：223 / 235

页数：13

共 43 条

[1] Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer [J].

Alvarez, Alvaro ;

Bernal, Ana M. M. ;

Anampa, Jesus .

BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) :75-88

[2]

[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043

[3] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J].

Beaver, Julia A. ;

Amiri-Kordestani, Laleh ;

Charlab, Rosane ;

Chen, Wei ;

Palmby, Todd ;

Tilley, Amy ;

Zirkelbach, Jeanne Fourie ;

Yu, Jingyu ;

Liu, Qi ;

Zhao, Liang ;

Crich, Joyce ;

Chen, Xiao Hong ;

Hughes, Minerva ;

Bloomquist, Erik ;

Tang, Shenghui ;

Sridhara, Rajeshwari ;

Kluetz, Paul G. ;

Kim, Geoffrey ;

Ibrahim, Amna ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4760-4766

[4] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[5] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer [J].

Chang, Jenny C. ;

O'Regan, Ruth .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 :S1-S14

[6] Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021 [J].

Chehayeb, Rachel Jaber ;

Hood, Annette ;

Wang, Xiaoliang ;

Miksad, Rebecca ;

Mougalian, Sarah Schellhorn ;

Lustberg, Maryam B. ;

Wang, Shi-Yi ;

Greenup, Rachel A. ;

Pusztai, Lajos ;

Kunst, Natalia .

JAMA NETWORK OPEN, 2022, 5 (11)

[7] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].

Cherny, N. I. ;

Sullivan, R. ;

Dafni, U. ;

Kerst, J. M. ;

Sobrero, A. ;

Zielinski, C. ;

de Vries, E. G. E. ;

Piccart, M. J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573

[8] The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making [J].

Cottu, Paul ;

Ramsey, Scott David ;

Sola-Morales, Oriol ;

Spears, Patricia A. ;

Taylor, Lockwood .

BREAST, 2022, 61 :118-122

[9] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[10] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes [J].

Ellis, Lee M. ;

Bernstein, David S. ;

Voest, Emile E. ;

Berlin, Jordan D. ;

Sargent, Daniel ;

Cortazar, Patricia ;

Garrett-Mayer, Elizabeth ;

Herbst, Roy S. ;

Lilenbaum, Rogerio C. ;

Sima, Camelia ;

Venook, Alan P. ;

Gonen, Mithat ;

Schilsky, Richard L. ;

Meropol, Neal J. ;

Schnipper, Lowell E. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1277-+

← 1 2 3 4 5 →